6 results about "Mycophenolate" patented technology

1. Name of the product in this design: Pharmaceutical Packaging Box (Mycophenolate Mofetil Dry Suspension). 2. Purpose of this design: For packaging pharmaceuticals. 3. The key design feature of this product is its pattern. 4. The image or photograph that best illustrates the design's key features: the front view.

The application provides a preparation method of sodium mycophenolate, which comprises the following steps: mixing mycophenolic acid crystals and first methanol, and obtaining first filtrate after first filtration treatment; mixing the first filtrate and a solid acid catalyst, and reacting at 50-55 DEG C until the content of mycophenolic acid is lower than 1%, and obtaining second filtrate after second filtration treatment; obtaining third filtrate after decolorization treatment and third filtration treatment of the second filtrate; obtaining first crystalline body after first crystallization treatment of the third filtrate; mixing the first crystalline body and second methanol, then adding sodium hydroxide and water, and reacting at 60-64 DEG C until the content of mycophenolate methyl ester is lower than 0.5%, and obtaining sodium mycophenolate concentrate after second crystallization treatment and reduced-pressure drying. By controlling the reaction degree of esterification and hydrolysis reactions and reasonably matching each step, the purity and yield of sodium mycophenolate can be improved.

The invention relates to the technical field of pharmaceutical preparations, in particular to a freeze-drying process of mycophenolate mofetil for injection, which comprises the following steps: cooling a mycophenolate mofetil injection to-35 DEG C to-45 DEG C, carrying out primary heat preservation, tempering and heating to-10 DEG C to-5 DEG C, carrying out secondary heat preservation, cooling to-40 DEG C to-50 DEG C, carrying out third heat preservation, and carrying out freeze-drying under the condition that the vacuum degree is 25-35Pa, so as to obtain the mycophenolate mofetil for injection. And heating the pre-frozen solid to-25 DEG C to-15 DEG C, preserving heat for four times, heating to 35-45 DEG C, and preserving heat for five times to obtain the freeze-dried mycophenolate mofetil for injection. Through the freeze-drying process, the total impurity content of a freeze-dried product is smaller than or equal to 0.15%, the medication safety and stability are remarkably improved, and the one-time sublimation drying time is greatly shortened to 9 h from 16 h in a traditional process; meanwhile, the residual moisture of the finished product is controlled to be about 0.1%, and the finished product can be stored at room temperature and meets the requirements of industrial large-scale production.

The invention discloses an LCMS / MS (Liquid Chromatography Mass Spectrometry / Mass Spectrometry) analysis and detection method for collinear residual impurities of mycophenolate mofetil capsules, and the LCMS / MS is adopted to analyze and detect a test sample in the step S1: chromatographic condition parameters are as follows: a chromatographic column with octadecylsilane chemically bonded silica as a filler is selected, the specification of the chromatographic column is 150mm * 4.6 mm, 2.7 mu m, and the column size is 1mm. A mobile phase is composed of an ammonium formate aqueous solution and an organic solvent mixed solution, and gradient elution is set according to the volume fraction; the flow velocity is 0.25 ml / min-0. 35 ml / min, the temperature of a chromatographic column is 38-42 DEG C, the temperature of a sample introduction disc is 5-10 DEG C, the sample introduction volume is 15-25 microliters, and mass spectrum condition parameters are as follows: an ion source is an electrospray ionization source, and the mode is a positive ion mode; and analyzing and detecting by adopting an external standard method. The method can effectively detect collinear residual impurities, and has the advantages of good sensitivity, high accuracy, high precision and good durability.

This invention provides a pharmaceutical composition and its application. The pharmaceutical composition of this invention comprises ribavirin and mycophenolate mofetil or a pharmaceutically acceptable salt thereof. The pharmaceutical composition of this invention can be used to prepare an antiviral drug, and the two active components exhibit a synergistic antiviral effect against influenza.

The invention discloses an application of chlorogenic acid in preparation of an antagonistic immunosuppressive drug neurotoxicity preparation, and particularly relates to a treatment method for nerve injury caused by mycophenolate mofetil (MMF). Through integration of network pharmacology, molecular docking and in-vivo and in-vitro experimental research, the protective effect of chlorogenic acid on MMF nerve injury is systematically verified, and the protective effect comprises biological effects of reducing neurotoxicity, promoting axon regeneration, inhibiting neuronal apoptosis and the like. Researches find that chlorogenic acid can be combined with a plurality of nerve injury related targets such as APP, CTSD, SRC, EGFR, ESR1, MMP2 and HSP90AA1 in a targeted manner, and a nerve protection effect is achieved through multi-way synergism. The invention provides a new intervention strategy for clinically relieving neurotoxic side effects of MMF, and has important theoretical value and clinical application prospect.